ArticleTranslational pediatrics2025
Efficacy and safety of dabrafenib-targeted therapy for pediatric langerhans cell histiocytosis: a systematic review and meta-analysis.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The presence of Methods: A systematic review and meta-analysis of nine studies was conducted across five electronic databases to assess the efficacy and safety of dabrafenib in children diagnosed with LCH, synthesizing data to provide a more comprehensive and reliable conclusion based on PRISMA 2020 Checklist. Results: The research protocol was pre-registered with PROSPERO (CRD420251046705). Our analysis revealed that dabrafenib significantly improved treatment outcomes for LCH children with an objective response rate (ORR) of 83% [95% confidence interval (CI): 70-91%], disease control rate (DCR) of 85% (95% CI: 68-94%), 1-year progression-free survival (PFS) of 80% (95% CI: 45-95%) and an acceptable safety profile characterized by manageable AEs (grade ≥3 AEs rate 2%). These outcomes emphasize the latent capacity of dabrafenib as a promising treatment option for pediatric LCH, particularly in cases harboring Conclusions: Our study supports the integration of dabrafenib into treatment protocols for pediatric LCH, especially children younger than 2 years, and highlighting the need for further prospective studies to validate these results and explore its long-term effects, ultimately aiming to enhance patient outcomes and alleviate the burden of this challenging disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.